An Adjuvanted, Postfusion F Protein-Based Vaccine Did Not Prevent Respiratory Syncytial Virus Illness in Older Adults

Judith Falloon, Jing Yu, Mark T Esser, Tonya Villafana, Li Yu, Filip Dubovsky, Therese Takas, Myron J Levin, Ann R Falsey, Judith Falloon, Jing Yu, Mark T Esser, Tonya Villafana, Li Yu, Filip Dubovsky, Therese Takas, Myron J Levin, Ann R Falsey

Abstract

Background: Respiratory syncytial virus (RSV) is an important cause of illness in older adults. This study assessed efficacy of a vaccine for prevention of RSV-associated acute respiratory illness (ARI), defined by specified symptoms with virologic confirmation.

Methods: This phase 2b study evaluated RSV postfusion F protein (120 µg) with glucopyranosyl lipid adjuvant (5 µg) in 2% stable emulsion. Subjects aged ≥60 years were randomly assigned at a ratio of 1:1 to receive vaccine or placebo (all received inactivated influenza vaccine). Ill subjects recorded symptoms and provided blood and nasal swab samples.

Results: In the per-protocol population (n = 1894), the incidence of RSV-associated ARI occurring ≥14 days after dosing was 1.7% and 1.6% in the vaccine and placebo groups, respectively, for a vaccine efficacy (VE) of -7.1% (90% confidence interval [CI], -106.9%-44.3%). Efficacy was not observed in secondary analyses that included seroresponse to nonvaccine RSV antigens (VE, 8.9%; 90% CI, -28.5%-35.4%) or symptoms combined with seroresponse (VE, 10.0%; 90% CI, -45.4%-44.4%). On day 29, 92.9% of vaccinees had an anti-F immunoglobulin G antibody seroresponse. Overall, 48.5% and 30.9% of RSV vaccine recipients reported local and systemic solicited symptoms, respectively.

Conclusion: The RSV vaccine was immunogenic but did not protect older adults from RSV illness.

Clinical trials registration: NCT02508194.

Keywords: Adjuvant; clinical trial; efficacy; respiratory syncytial virus; subunit; vaccine.

© The Author 2017. Published by Oxford University Press for the Infectious Diseases Society of America.

Figures

Figure 1.
Figure 1.
Disposition of subjects (as treated; 1 subject who was randomly assigned to receive respiratory syncytial virus (RSV) vaccine received placebo in error). IIV, inactivated influenza vaccine; PI, principal investigator. aCompleted efficacy follow-up.
Figure 2.
Figure 2.
Forest plot of vaccine efficacy (VE) for the first episode of acute respiratory syncytial virus (RSV)–associated respiratory illness (ARI) or by seroresponse in the per protocol (PP) population. Assessment was during the surveillance period, starting 14 days after dosing, unless otherwise noted. A, Efficacy according to RSV-associated ARI definition (first episode of RSV-associated ARI symptoms plus RSV detection in respiratory specimen by polymerase chain reaction analysis). B, Efficacy according to seroresponse definition (ie, RSV-associated ARI symptoms plus seroresponse to nonvaccine antigens). CI, confidence interval; ITT, intention to treat; LRTI, lower respiratory tract illness.
Figure 3.
Figure 3.
Anti–respiratory syncytial virus (RSV) fusion protein immunoglobulin G (IgG) antibody results at baseline, day 29, and the end of the RSV infection season. CI, confidence interval.
Figure 4.
Figure 4.
Geometric mean respiratory syncytial virus (RSV) microneutralizing (MN) antibody titer (A) and palivizumab-competitive antibody (PCA) values (B) at baseline and on day 29 after dosing in subjects who met the primary end point or were selected to match them (in a 1:6 ratio) or to match the sample size of a group that received the same formulation in a phase 1b study (clinical trials registration: NCT02289820) through random sampling stratified by age and sex and controlled over baseline anti–RSV fusion protein immunoglobulin G levels, region, and comorbidity status. C, Cell-mediated response to RSV, as measured by RSV interferon γ enzyme-linked immunospot assay, in subjects who met the primary end point or who were randomly selected on the basis of sample availability. CI, confidence interval; IC50, inhibitory concentration at 50%; SFC, spot-forming cells.

References

    1. Falsey AR, Hennessey PA, Formica MA, Cox C, Walsh EE. Respiratory syncytial virus infection in elderly and high-risk adults. N Engl J Med 2005; 352:1749–59.
    1. Hall CB, Walsh EE, Long CE, Schnabel KC. Immunity to and frequency of reinfection with respiratory syncytial virus. J Infect Dis 1991; 163:693–8.
    1. Falsey AR, Walsh EE. Relationship of serum antibody to risk of respiratory syncytial virus infection in elderly adults. J Infect Dis 1998; 177:463–6.
    1. Malloy AMW, Falsey AR, Ruckwardt TJ. Consequences of immature and senescent immune responses for infection with respiratory syncytial virus. In: Anderson LJ, Graham BS, eds. Challenges and opportunities for respiratory syncytial virus vaccines. Berlin, Heidelberg: Springer Berlin Heidelberg, 2013:211–231.
    1. Walsh EE, Peterson DR, Falsey AR. Risk factors for severe respiratory syncytial virus infection in elderly persons. J Infect Dis 2004; 189:233–8.
    1. Cherukuri A, Patton K, Gasser RA Jr et al. . Adults 65 years old and older have reduced numbers of functional memory T cells to respiratory syncytial virus fusion protein. Clin Vaccine Immunol 2013; 20:239–47.
    1. Graham BS, Modjarrad K, McLellan JS. Novel antigens for RSV vaccines. Curr Opin Immunol 2015; 35:30–8.
    1. Langley JM, Aggarwal N, Toma A et al. . A randomized, controlled, observer-blinded phase 1 study of the safety and immunogenicity of a respiratory syncytial virus vaccine with or without alum adjuvant. J Infect Dis 2017; 215:24–33.
    1. Melero JA, Mas V, McLellan JS. Structural, antigenic and immunogenic features of respiratory syncytial virus glycoproteins relevant for vaccine development. Vaccine 2017; 35:461–8.
    1. Collins PL, Melero JA. Progress in understanding and controlling respiratory syncytial virus: still crazy after all these years. Virus Res 2011; 162:80–99.
    1. Lambert SL, Yang CF, Liu Z et al. . Molecular and cellular response profiles induced by the TLR4 agonist-based adjuvant glucopyranosyl lipid A. PLoS One 2012; 7:e51618.
    1. Falloon J, Ji F, Curtis C et al. . A phase 1a, first-in-human, randomized study of a respiratory syncytial virus F protein vaccine with and without a toll-like receptor-4 agonist and stable emulsion adjuvant. Vaccine 2016; 34:2847–54.
    1. Falloon J, Talbot K, Curtis C et al. . Dose selection for an adjuvanted respiratory syncytial virus F protein vaccine for older adults based on humoral and cellular immune responses. Clin Vaccine Immunol 2017. In press. doi: 10.1128/CVI.00157-17.
    1. Lambert SL, Aslam S, Stillman E et al. . A novel respiratory syncytial virus (RSV) F subunit vaccine adjuvanted with GLA-SE elicits robust protective TH1-type humoral and cellular immunity in rodent models. PLoS One 2015; 10:e0119509.
    1. Patton K, Aslam S, Shambaugh C et al. . Enhanced immunogenicity of a respiratory syncytial virus (RSV) F subunit vaccine formulated with the adjuvant GLA-SE in cynomolgus macaques. Vaccine 2015; 33:4472–8.
    1. Powers JH, Guerrero ML, Leidy NK et al. . Development of the Flu-PRO: a patient-reported outcome (PRO) instrument to evaluate symptoms of influenza. BMC Infect Dis 2016; 16:1.
    1. Powers JH, Stringer S, Clifford S et al. . Development of the patient-reported outcome (PRO) instrument FLU-PRO to standardize and quantify symptoms of influenza. Presented at: 2nd Joint Meeting of the Infectious Diseases Society of America, the Society for Healthcare Epidemiology of America, the HIV Medicine Association, and the Pediatric Infectious Diseases Society, IDWeek 2013: Advancing Science, Improving Care, San Francisco, CA, 2–6 October 2013.
    1. Maifeld SV, Ro B, Mok H et al. . Development of electrochemiluminescent serology assays to measure the humoral response to antigens of respiratory syncytial virus. PLoS One 2016; 11:e0153019.
    1. Patton K, Aslam S, Lin J et al. . Enzyme-linked immunospot assay for detection of human respiratory syncytial virus f protein-specific gamma interferon-producing T cells. Clin Vaccine Immunol 2014; 21:628–35.
    1. McClure DL, Kieke BA, Sundaram ME et al. . Seasonal incidence of medically attended respiratory syncytial virus infection in a community cohort of adults ≥50 years old. PLoS One 2014; 9:e102586.
    1. Centers for Disease Control and Prevention (CDC). People at high risk of developing flu-related complications . Accessed 5 August 2016.
    1. Grohskopf LA, Shay DK, Shimabukuro TT et al. . Prevention and control of seasonal influenza with vaccines: recommendations of the Advisory Committee on Immunization Practices—United States, 2013–2014. MMWR Morb Mortal Wkly Rep 2014; 63:691–7.
    1. Breslow NE, Day NE. Statistical methods in cancer research. Volume II–the design and analysis of cohort studies. IARC Sci Publ 1987; 82:1–406.
    1. Chan ISF, Bohidar NR. Exact power and sample size for vaccine efficacy studies. Commun Stat Theory Methods 1998; 27:1305–22.
    1. Duvvuri VR, Granados A, Rosenfeld P, Bahl J, Eshaghi A, Gubbay JB. Genetic diversity and evolutionary insights of respiratory syncytial virus A ON1 genotype: global and local transmission dynamics. Sci Rep 2015; 5:14268.
    1. Trento A, Casas I, Calderón A et al. . Ten years of global evolution of the human respiratory syncytial virus BA genotype with a 60-nucleotide duplication in the G protein gene. J Virol 2010; 84:7500–12.
    1. Falsey AR, Singh HK, Walsh EE. Serum antibody decay in adults following natural respiratory syncytial virus infection. J Med Virol 2006; 78:1493–7.
    1. Walsh EE, Falsey AR. Humoral and mucosal immunity in protection from natural respiratory syncytial virus infection in adults. J Infect Dis 2004; 190:373–8.
    1. McLellan JS, Yang Y, Graham BS, Kwong PD. Structure of respiratory syncytial virus fusion glycoprotein in the postfusion conformation reveals preservation of neutralizing epitopes. J Virol 2011; 85:7788–96.
    1. Fuentes S, Coyle EM, Beeler J, Golding H, Khurana S. Antigenic fingerprinting following primary RSV infection in young children identifies novel antigenic sites and reveals unlinked evolution of human antibody repertoires to fusion and attachment glycoproteins. PLoS Pathog 2016; 12:e1005554.
    1. Ngwuta JO, Chen M, Modjarrad K et al. . Prefusion F–specific antibodies determine the magnitude of RSV neutralizing activity in human sera. Sci Transl Med 2015; 7:309ra162.
    1. O’Brien KL, Chandran A, Weatherholtz R et al. ; Respiratory Syncytial Virus (RSV) Prevention study group Efficacy of motavizumab for the prevention of respiratory syncytial virus disease in healthy Native American infants: a phase 3 randomised double-blind placebo-controlled trial. Lancet Infect Dis 2015; 15:1398–408.
    1. Bloom-Feshbach K, Alonso WJ, Charu V et al. . Latitudinal variations in seasonal activity of influenza and respiratory syncytial virus (RSV): a global comparative review. PLoS One 2013; 8:e54445.
    1. Falsey AR, Walsh EE, Capellan J et al. . Comparison of the safety and immunogenicity of 2 respiratory syncytial virus (RSV) vaccines–nonadjuvanted vaccine or vaccine adjuvanted with alum–given concomitantly with influenza vaccine to high-risk elderly individuals. J Infect Dis 2008; 198:1317–26.
    1. Schuster JE, Cox RG, Hastings AK et al. . A broadly neutralizing human monoclonal antibody exhibits in vivo efficacy against both human metapneumovirus and respiratory syncytial virus. J Infect Dis 2015; 211:216–25.
    1. Wen X, Mousa JJ, Bates JT, Lamb RA, Crowe JE Jr, Jardetzky TS. Structural basis for antibody cross-neutralization of respiratory syncytial virus and human metapneumovirus. Nat Microbiol 2017; 2:16272.

Source: PubMed

Szponzorok és közreműködők

Egészségi állapot

Kábítószer-beavatkozások

3
Iratkozz fel